Aptimmune Achieves Industry First with Mucosal Swine Flu Vaccine

November 17, 2017

Aptimmune Biologics, Inc. once again breaks through industry barriers by commercializing the first inactivated musosal vaccine for Influenza A virus in swine, administered via nasal spray. This vaccine helps provide veternarians and swine producers a new way to combat these diseases that can create costly and horrific results as they spread through swine. The vaccine is safe to use, and accurately manages these respirtatory diseases. 

The new vaccine is available in 250-mL and 500-mL bottles, an Aptimmune recommends the swine be vaccinated once at 7-10 days old and then again during weaning, at 3-4 weeks of age. 

Aptimmune Biologics is a startup located at EnterpriseWorks that specializes in developing and marketing a portfolio of revolutionary musosal vaccines that provide answers for the most costly viral diseases that impact swine industry. 

Read more here.